<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262561</url>
  </required_header>
  <id_info>
    <org_study_id>2005-003844-68</org_study_id>
    <nct_id>NCT00262561</nct_id>
  </id_info>
  <brief_title>Resistance to Aspirin and/or Clopidogrel Among Patients With PAD.</brief_title>
  <official_title>Prevalence of Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Prognostic Significance of Resistance to Aspirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      263 patients with peripheral atherosclerosis were examined to evaluate the activity of the&#xD;
      platelets during the standard treatment, including aspirin. A subgroup of 43 received 600 mg&#xD;
      of clopidogrel 2 h before platelet reactivity analysis.&#xD;
&#xD;
      The main hypothesis is that high platelet activity at the beginning of the study is&#xD;
      associated with a higher risk of atherothrombosis. Follow up time is 5 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with peripheral atherosclerosis are at high risk of atherothrombosis, mainly heart&#xD;
      attack and stroke. The medical treatment of these patients include platelet inhibiting drugs,&#xD;
      usually aspirin, to reduce the risk of ischemic events. Clopidogrel is another platelet&#xD;
      inhibiting drug, which is prescribed less often, primarily because of the high costs compared&#xD;
      to aspirin.&#xD;
&#xD;
      Phenomena of 'resistance' to these drugs have been described by numerous investigators.&#xD;
      Essentially resistance means that the effect of the drug described is less than expected or&#xD;
      missing, as measured by various laboratory methods. We do not know which way resistance is&#xD;
      best described, but it has been described that patients who are 'resistant' to either drug&#xD;
      are less protected against future heart attacks or strokes.&#xD;
&#xD;
      Main objectives:&#xD;
&#xD;
        -  To measure the activity of platelets in these patients during aspirin treatment.&#xD;
&#xD;
        -  To measure the activity of platelets in a minor population of these patients during&#xD;
           clopidogrel treatment.&#xD;
&#xD;
        -  To evaluate the prognostic significance of resistance to aspirin in these patients.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Platelet activity is measured by the PFA-100 (Dade Behring) and by traditional turbidimetric&#xD;
      aggregation.&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Myocardial infarction, unstable angina, cerebral infarction, transitory cerebral ischaemia,&#xD;
      sudden deterioration of symptoms, percutaneous or surgical vascular intervention, amputation,&#xD;
      death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial infarction, Unstable angina, Cerebral infarction, Transitory cerebral ischaemia, Percutaneous or surgical vascular intervention, Sudden deterioration of symptoms, Amputation, Death.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">263</enrollment>
  <condition>Intermittent Claudication</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All participants get Aspirin, and platelet reactivity measurements are performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>The effect of Aspirin on platelet function was assessed.</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Atherosclerosis of the lower limbs, defined by one of the following criteria:&#xD;
             Ankle-Brachial Pressure Index (ABPI)&lt; 0.9, intermittent claudication, ischaemic pain&#xD;
             at rest, ischaemic ulcers or gangrene.&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  For fertile women: Use of safe contraception (intrauterine contraceptive device, the&#xD;
             pill, hormonal skin patches, progestogen injections, progestogen implant, vaginal&#xD;
             ring)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to either Aspirin or Clopidogrel&#xD;
&#xD;
          -  Known bleeding disorder&#xD;
&#xD;
          -  Platelet count &lt; 140 mia/L or &gt; 400 mia/L&#xD;
&#xD;
          -  Intake of NSAID's, SSRI's or Dipyridamol within the preceding 14 days&#xD;
&#xD;
          -  Not radically treated gastrointestinal ulceration within the last 6 month&#xD;
&#xD;
          -  Greater surgical procedures performed within the last 3 month&#xD;
&#xD;
          -  Severe renal disease&#xD;
&#xD;
          -  Severe hepatic disease&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nils Johannesen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Vascular Surgery, Aalborg Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Vascular Surgery, Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>December 6, 2005</study_first_submitted>
  <study_first_submitted_qc>December 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2005</study_first_posted>
  <last_update_submitted>January 25, 2014</last_update_submitted>
  <last_update_submitted_qc>January 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Esben Hjorth Madsen</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Intermittent Claudication</keyword>
  <keyword>Aspirin resistance</keyword>
  <keyword>Clopidogrel resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

